AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression

Recruitingn/aAges 18 Years - 99 YearsAllPneumonia Research Network on Genetic Resistance …
💬

In plain words

What the trial is, and whether it could suit you

Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization. However, the course of disease of patients in the hospital remains hard to predict. While most patients will recover quickly, some will, despite appropriate treatment, develop a severe course leading to sepsis and systemic responses resulting in organ dysfunction. The PROGRESS consortium aims to identify clinical, genetic, and other molecular markers and combinations there of predicting a severe course of pneumonia in the hospital. Such predictors will, for instance, support decisions on earlier transfer of patients to intensive care and thus improving outcome. PROGRESS-COMORB aims to extend findings from the previous PROGRESS study to patients with more severe preexisting conditions and immunosuppress

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Hospitalization with community acquired pneumonia (CAP) confirmed by pulmonary infiltrate in chest imaging 2. Valid informed consent form 3. Working diagnosis of CAP by enrolling physician 4. No hospitalization for any reason within 28 days prior to hospitalization for the current episode of CAP 5. At least 2 out of the five following clinical symptoms: * Fever * Cough * Purulent sputum * Shortness of breath or need for respiratory support * Crackling or rales on auscultation, dullness to percussion, or bronchial breathing 6. At least 1 of the following criteria * Known HIV infection or AIDS * Anti-tumor treatment within the past six months * Therapy with corticosteroids ≥ 20mg for ≥ 14 days before enrollment * Non-steroidal immunosuppressive therapy within the past six months * Cytostatic therapy within the past six months * Radiation therapy within the past six months * Bone marrow transplant received * Respiratory support at home via tracheostoma * Cystic fibrosis * Heart failure: New York Heart Association (NYHA) Stadium IV or HFrEF (defined as left ventricular ejection fraction \<40%). * Decompensated liver disease (Child-Pugh class C) * Diabetes mellitus with HbA1c ≥ 8,5 % * End-stage renal disease requiring dialysis * Pulmonary hypertension (all classes) with mPAP \> 20 mmHg (right heart catheter) Exclusion Criteria: 1. Participation in this study at an earlier time 2. More than 48 hours in the hospital before enrollment (for patients directly to intensive care: more than 7 days) 3. Pregnancy 4. Breastfeeding 5. Active tuberculosis 6. Acute lung injury or acute respiratory distress syndrome for extrapulmonary reasons 7. Massive aspiration 8. Sepsis with extrapulmonary focus 9. Acute pulmonary embolism
💊

What it tests

  • Not listed
📍

Where

10 sites
Charité - Universitätsmedizin Berlin, Medizinische Klinik m. S. Infektiologie und Pneumologie
Berlin, Germany
Humboldt-Klinikum Vivantes, Kardiologie und kons. Intensivmedizin
Berlin, Germany
Gemeinschaftskrankenhaus Havelhöhe, Kardio-Pneumologie
Berlin, Germany
Städtisches Klinikum Dessau, Innere Medizin
Dessau, Germany
Universitätsklinikum Hamburg Eppendorf, Onkologisches Zentrum, Pneumologische Studienzentrale
Hamburg, Germany
Universitätsklinikum Leipzig, Klinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie
Leipzig, Germany
Klinikum St. Georg gGmbH, Klinik für Infektions-/Tropenmedizin und Nephrologie
Leipzig, Germany
Universitätsklinikum Gießen und Marburg, Klinik für Pneumologie und Anästhesie
Marburg, Germany

…and 2 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy